美国泌尿科与非泌尿科医生对勃起功能障碍的流行病学与诊断:全国门诊医疗调查分析
基于2006至2016年美国全国门诊医疗调查的170499次男性就诊数据分析,1.2%与勃起功能障碍(ED)诊断相关,年加权就诊量达3409244次。ED就诊主要由泌尿科医生(58.0%)和家庭医生(26.2%)接诊;非泌尿科医生更常开具磷酸二酯酶-5抑制剂(66.62% vs 50.77%),而泌尿科医生更常使用 advanced 疗法(2.72% vs 0.25%)。
要点
- ED就诊中近半由非泌尿科医生接诊,其较少处方 advanced 疗法。
- 非泌尿科医生更倾向开具磷酸二酯酶-5抑制剂(66.62% vs 50.77%)。
- 泌尿科医生接诊的ED患者中活跃癌症诊断比例更高(24.2% vs 2.8%)。
核心结论
- 近半数ED就诊由非泌尿科医生接诊,其处方 advanced 药物的比例显著低于泌尿科医生。
- 不同专科处方模式的差异为跨学科协作和教育提供了机会,以确保ED患者获得基于指南的诊疗。
研究设计与样本
- 研究分析了2006至2016年美国全国门诊医疗调查(NAMCS)中所有男性患者就诊记录,共170499次就诊。
- 通过卡方检验比较泌尿科与非泌尿科医生接诊的ED患者的人口学、临床和治疗特征。
主要发现
- 在170499次就诊中,1.2%与ED诊断相关,年加权就诊量为3409244次。
- ED就诊主要由泌尿科医生(58.0%)和家庭医生(26.2%)接诊。
- 非泌尿科医生接诊的ED患者更可能年龄小于65岁(77.4% vs 52.9%,P < .05)。
- 泌尿科医生接诊的ED患者更常有活跃癌症诊断(24.2% vs 2.8%,P < .05)。
- 非泌尿科医生更常开具或续开磷酸二酯酶-5抑制剂(66.62% vs 50.77%,P < .05)。
临床怎么用
- 泌尿科医生应关注非泌尿科医生接诊的ED患者,尤其是年轻患者,促进跨学科协作以优化治疗。
- 非泌尿科医生在开具磷酸二酯酶-5抑制剂时,可考虑对需要 advanced 疗法的患者及时转诊泌尿科。
局限性
- 研究为回顾性调查数据分析,可能存在编码偏倚和未测量混杂因素。
- NAMCS数据依赖医生报告,可能低估或高估ED诊断和治疗的真实情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the extent to which erectile dysfunction (ED) is managed by urologists versus non-urologists. We sought to characterize the epidemiology, diagnosis, and outpatient treatment of ED using a nationally representative cohort. METHODS: We examined all male patient visits between 2006 and 2016 in the National Ambulatory Medical Care Survey, a survey designed to provide a nationally representative estimate of ambulatory visits in the United States. Distribution of ED diagnoses among physician specialties was determined. Demographic, clinical, and treatment characteristics of men with ED seeing urologists versus non-urologists were compared using chi-squared tests. RESULTS: Among the 170,499 patient visits analyzed, 1.2% were associated with a diagnosis of ED, which translated into 3,409,244 weighted visits annually. Visits for ED were predominantly seen by urologists (58.0%) and family practitioners (26.2%). Men visiting non-urologists for ED were more likely to be younger than 65 (77.4% vs 52.9%, P < .05). Men seeing urologists for ED more frequently had an active cancer diagnosis (24.2% vs 2.8%, P < .05). Non-urologists more readily ordered or reordered phosphodiesterase-5 inhibitors for men with ED (66.62% vs 50.77%, P < .05). Advanced therapies such as intracavernosal injections and intra-urethral agents were almost exclusively ordered by urologists compared to non-urologists (2.72% vs 0.25%, P < .05). CONCLUSION: Almost half of all ED visits were seen by non-urologist providers, who were much less likely than urologists to order advanced pharmacologic therapies. This difference in prescribing patterns presents an opportunity for interdisciplinary collaboration and education to ensure that all patients seeking treatment for ED are receiving guideline-based care.
引用
- Panken EJ, Fantus RJ, Chang C, et al. Epidemiology and Diagnosis of Erectile Dysfunction by Urologists Versus Non-Urologists in the United States: An Analysis of the National Ambulatory Medical Care Survey. Urology. 2020. PMID: 32979379. doi:10.1016/j.urology.2020.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。